| Literature DB >> 24708560 |
Helen A Banwell1, Shylie Mackintosh, Dominic Thewlis.
Abstract
BACKGROUND: Foot orthoses are widely used in the management of flexible pes planus, yet the evidence to support this intervention has not been clearly defined. This systematic review aimed to critically appraise the evidence for the use of foot orthoses for flexible pes planus in adults.Entities:
Year: 2014 PMID: 24708560 PMCID: PMC4108129 DOI: 10.1186/1757-1146-7-23
Source DB: PubMed Journal: J Foot Ankle Res ISSN: 1757-1146 Impact factor: 2.303
Figure 1Flow chart of study selection.
Table of included studies; level of evidence, cohort characteristics and type of FOs used
| Rome and Brown [ | II | RCT | 50 (25/25) | Excessive pronators | 23.8 (2.2) | FPI-8 | Physical function | Talar made © | EVA | 5° | 0° |
| Esterman and Pilotto [ | II | RCT | 47 (25/22) | Air force recruits | 21.6 (3.9) | AI | Pain | AOL® | Plastic | 4° | 4° |
| Otman et al. [ | III-2 | CCT | 20 (20/20) | Female adults | 25.8 (1.3) | Radiographs | Physical function | Arch supports | Polypropylene | 0° | 0° |
| Zifchock and Davis [ | IV | RM | 19 | Low arched recreation runners | 23.6 (6.4) | AHI | Rearfoot kinematics | A. Modified Root device | Graphite | 0 – 7° | 0° |
| B. KLM® | Graphite | NR | NR | ||||||||
| Mündermann et al. [ | IV | RM | 21 | Recreational runners | 25.4 (5.6) | RE | Rearfoot kinematics and kinetics | A. Modified Root device | Polypropylene | 6 mm | 6 mm |
| B. Modified Root device | Polypropylene | 0° | 0° | ||||||||
| C. Pre-made Insert | EVA | 6 mm | 6 mm | ||||||||
| Cobb et al. [ | IV | RM | 16 | Low mobile arch adults | 25.4 (6.5) | AHI | Rearfoot kinematics | A. MASS Device | Polyethylene composite | 0° | 0° |
| B. Modified Root device | Leather and composite material | NR | NR | ||||||||
| Murley et al. [ | IV | RM | 30 | Adults | 21.8 (4.3) | AI & NH | Physical function | A. Inverted (Blake) device | Polypropylene | 20 ° | 0° |
| B. Formthotic ® | Duel density polyethylene foam | 6 mm | 0° | ||||||||
| Redmond et al. [ | IV | RM | 22 | Excessive pronators | 24 | RE | Kinetics | A. Modified Root device | Polypropylene | 6° | 0° |
| B. Pre-made Insert | Thin card with EVA posts | 6° | 0° | ||||||||
| Zammit and Payne [ | IV | RM | 22 | Excessive RF pronators (clinical practice) | 44.3 (16.7) | FPI-8 | Pain and physical function | Independently prescribed | Variable | IP | IP |
| Murley and Bird [ | IV | RM | 17 | Adults | 23.0 (5.0) | FPI-6 | Physical function | A. Inverted (Blake) device | NR | 30 ° | 0° |
| B. Inverted (Blake) device | NR | 15° | 0° | ||||||||
| C. Inverted (Blake) device | NR | 0° | 0° | ||||||||
| Hurd et al. [ | IV | RM | 15 | Recreational runners | 34.0 (10.0) | FF to RF | Rearfoot kinematics and kinetics | A. Flat foot Insert © | Polyurethane with a poron layer | 0° | 4° |
| B. SofSole® | Graphite Polyurethane | 0° | 0° | ||||||||
| Johanson et al. [ | IV | RM | 22 | Physical therapy attendees (clinical practice) | 30.5 (8.0) | FF to RF | Rearfoot kinematics | A. Orthofeet Biothotics© | Water injected polyurethane shells with EVA posting | 80% of FF post | Up to 7 mm |
| B. Orthofeet Biothotics© | As above | 80% of FF post | 0° | ||||||||
| C. Orthofeet Biothotics© | As above | 0° | Up to 7 mm | ||||||||
| D. Orthofeet Biothotics© | As above | 0° | 0° | ||||||||
| Chen et al. [ | IV | RM | 11 | Adults | 45.9 (15.7) | AI | Kinetics and physical function | NR | Vinyl-acetate & 12% far-infrared nanopowders | NR | NR |
RM – repeated measure. CCT – controlled clinical trial. AHI – arch height index, AI – arch index, FF to RF – forefoot to rearfoot relationship, NH – navicular height, FPI-8 – Foot Posture Index – 8- item version, FPI-6 – Foot Posture Index – 6- item version, RE- rearfoot eversion. MASS – maximum subtalar supination position, NR – not reported, FF – forefoot, EVA -ethyl vinyl acetate.
Orthotic Labs: Formthotic (Foot Science International, Christchurch, New Zealand) Flatfoot insert, (Hickory Brands, Inc, Hickory, NC, USA), Sofsole, LLC, Durham, NC), KLM (KLM Orthotic Laboratories; Valencia, CA, USA), AOL (Australian Orthotics Laboratory, International, Kirrance, NSW, Australia), Talar made (Talar Made Orthotics, Chesterfield, UK), Orthofeet Biothotics (Orthofeet Inc, Hillsdale, NJ, USA).
Relevant outcome measures related to the domain of pain (significant SMD results are bolded)
| Esterman and Pilotto [ | 10 week basic air force training recorded at baseline and 8 weeks | VAS 0 – 10, pain previous 24 hours following 8 weeks of FO use | 1.14 (2.4) | NA | 0.68 (1.5) |
| Zammit and Payne [ | FHSQ reported at baseline and 4 weeks | Increase in FHSQ pain subscale following 4 weeks of FO use (reduction in pain) | 49.84 (24.8) | NA |
VAS – visual analogue scale, FO – foot orthoses, FHSQ – foot health status questionnaire, NA – not applicable.
Relevant outcome measures related to the domain of rearfoot kinematics (significant SMD results are bolded) - walking unless otherwise noted
| Zifchock and Davis [ | Over-ground walking (2.0 m/s) in low arch cohort | Peak RF eversion (°) | 4.31 (2.5) | A | 5.45 (5.1) |
| B | 4.38 (2.2) | ||||
| RF eversion excursion (°) | 10.60 (2.8) | A | 9.47 (1.9) | ||
| B | 9.68 (1.8) | ||||
| Peak RF eversion velocity (°/s) | 155.65 (46.9) | A | 141.50 (47.2) | ||
| B | 144.78 (46.5) | ||||
| Mündermann et al. [ | Over-ground running (4.0 ± 0.2 m/s) in recreational runners with everted rearfoot. | Peak foot eversion (°) * | 16.00 (2.3) | A | 16.90 (3.6) |
| B | 16.60 (2.5) | ||||
| C | |||||
| Peak foot eversion velocity (°/s) * | 464.70 (155.2) | A | 484.40 (141.1) | ||
| B | 476.80 (145.0) | ||||
| C | 392.90 (135.0) | ||||
| Cobb et al. [ | Over-ground walking (1.3 to 1.4 m/s) in low arch cohort | RF eversion excursion (terminal stance (°) | 0.85 (0.8) | A | 0.28 (0.5) |
| 0.02 (0.4) | B | 0.18 (0.3) | |||
| Hurd et al. [ | Over-ground walking (1.2 m/s ± 5%) in forefoot varus cohort | RF eversion (initial contact) (°) | -1.60 (3.6) | A | -1.00 (3.1) |
| B | -0.30 (4.0) | ||||
| Peak RF eversion (loading) (°) | -3.40 (3.7) | A | -2.80 (5.6) | ||
| B | -2.70 (5.3) | ||||
| Over-ground running (1.7 m/s ± 5%) in forefoot varus cohort | RF eversion (initial contact) (°) * | -3.30 (4.0) | A | -2.50 (5.0) | |
| B | -2.30 (4.5) | ||||
| Peak RF eversion (loading) (°) * | -5.60 (3.5) | A | -5.30 (10.5) | ||
| B | -5.60 (11.1) | ||||
| Johanson et al. [ | Treadmill walking (1.11 m/s) in forefoot varus cohort | Peak RF eversion (°) | 0.80 (3.0) | A | |
| B | -0.88 (3.3) | ||||
| C | -0.44 (3.3) | ||||
| D | -0.36 (3.0) |
FO – foot orthoses, RF – rearfoot, FF – forefoot, *during running.
Relevant outcome measures related to the domain of kinetics (force and joint moment change) (significant SMD results are bolded) –during walking unless otherwise noted
| Mündermann et al. [ | Over-ground running (4.0 ± 0.2 m/s) | Vertical impact peak (N) | 1499.10 (255.6) | A | 1352.30 (233.6) |
| B | 1400.40 (242.5) | ||||
| C | 1519.40 (265.9) | ||||
| Peak loading rate (N/s) | 52.50 (11.1) | A | |||
| B | |||||
| C | 53.5 (11.9) | ||||
| Redmond et al. [ | Over-ground walking (self-selected speed) | Peak force (heel) (N) | 544.50 (104.3) | A | 501.90 (97.3) |
| B | 543.80 (100.6) | ||||
| Peak force (midfoot) (N) | 195.30 (62.7) | A | |||
| B | 156.20 (73.9) | ||||
| Peak force (lateral FF) (N) | 426.90 (12.1) | A | 396.90 (110.3) | ||
| B | 429.90 (122.0) | ||||
| Peak force (medial FF) (N) | 188.50 (62.9) | A | 173.20 (65.4) | ||
| B | 190.00 (72.2) | ||||
| Peak force (hallux) (N) | 148.90 (63.1) | A | 161.40 (54.9) | ||
| B | 159.90 (53.9) | ||||
| Force-time integral (heel) (N/s) | 1436.20 (462.2) | A | 1285.00 (385.3) | ||
| B | 1488.90 (441.1) | ||||
| Force-time integral (midfoot) (N/s) | 527.70 (224.4) | A | |||
| B | 454.40 (253.5) | ||||
| Force-time integral (lateral FF) (N/s) | 1394.70 (575.1) | A | |||
| B | 1317.00 (520.5) | ||||
| Force-time integral (medial FF) (N/s) | 468.50 (212.1) | A | |||
| B | 423.50 (202.5) | ||||
| Force-time integral (hallux) (N/s) | 294.90 (141.5) | A | 304.60 (155.7) | ||
| B | 317.70 (145.3) | ||||
| Mündermann et al. [ | Over-ground running (4.0 ± 0.2 m/s) | Peak ankle inversion moment (Nm.kg-1) | 0.47 (0.1) | A | 0.40 (0.1) |
| B | 0.43 (0.1) | ||||
| C | |||||
| Time of ankle inversion moment (% of gait cycle) | 41.00 (5.5) | A | 39.90 (6.5) | ||
| B | 41.40 (6.7) | ||||
| C | 40.20 (5.5) | ||||
| Hurd et al. [ | Over-ground walking (1.2 m/s ± 5%) | Peak RF moment (Nm.kg-1) | 0.78 (0.4) | A | 0.74 (0.5) |
| B | 0.88 (0.3) | ||||
| Mean RF moment (Nm.kg-1) | 0.04 (0.4) | A | -0.18 (0.5) | ||
| B | 0.19 (0.5) | ||||
| Over-ground running (1.7 m/s ± 5%) | Peak RF moment (Nm.kg-1) | 1.75 (0.7) | A | ||
| B | 1.76 (0.7) | ||||
| Mean RF moment (Nm.kg-1) | 0.71 (1.0) | A | 0.09 (1.0) | ||
| B | 0.92 (0.8) |
FO – foot orthoses, DF – dorsiflexion, PF – plantarflexion, RF – rearfoot, NA – not applicable.
Relevant outcome measures related to changes in: physical function (significant SMD results are bolded) – outcomes are measured during walking unless otherwise noted
| Rome and Brown [ | Quiet standing | Mean of the 300 balance points measured over 30 seconds (%) | 49.40*^ | NA | 46.10*^ |
| Medial to lateral sway - rate of deviation from the mean balance over 30 seconds (%) | 1.90*^ | NA | |||
| Anterior to posterior sway - rate of deviation from the mean balance over 30 seconds (%) | 4.60*^ | NA | 4.80*^ | ||
| Otman et al. [ | Walking on treadmill at 1.34 m/s | Energy cost (ml/kg/min) | 13.90* | NA | |
| Murley et al. [ | Over-ground walking (self-selected ± 5%) | TP EMG peak amplitude (initial contact and loading)% | 101.91 (33.9) | A | 89.51 (36.8) |
| B | |||||
| TP EMG RMS amplitude (initial contact and loading)% | 101.94 (30.9) | A | 89.37 (33.6) | ||
| B | |||||
| TP EMG peak amplitude (midstance, terminal and pre-swing) (% of gait cycle) | 90.96 (28.8) | A | 89.62 (22.2) | ||
| B | 87.34 (27.3) | ||||
| TP EMG RMS amplitude (midstance, terminal and pre-swing)% | 89.60 (24.1) | A | 86.92 (17.83) | ||
| B | 85.84 (23.9) | ||||
| PL EMG peak amplitude (initial contact and loading)% | 80.16 (35.6) | A | 84.70 (42.1) | ||
| B | 90.48 (47.3) | ||||
| PL EMG RMS amplitude (initial contact and loading)% | 79.44 (27.6) | A | 84.25 (37.5) | ||
| B | 98.10 (44.6) | ||||
| PL EMG peak amplitude (midstance, terminal and pre-swing) (% of gait cycle) | 62.71 (32.6) | A | 67.78 (33.9) | ||
| B | |||||
| PL EMG RMS amplitude (midstance, terminal and pre-swing)% | 71.90 (39.9) | A | 79.86 (46.0) | ||
| B | |||||
| TA EMG peak amplitude (initial contact and loading)% | 116.32 (15.8) | A | 113.49 (15.3) | ||
| B | 111.50 (17.4) | ||||
| TA EMG RMS amplitude (initial contact and loading)% | 122.02 (19.8) | A | 119.79 (22.0) | ||
| B | 113.00 (22.3) | ||||
| TP EMG time of peak amplitude (initial contact and loading) (% of gait cycle) | 10.94 (1.7) | A | 11.37 (2.1) | ||
| B | 11.10 (2.2) | ||||
| TP EMG time of peak amplitude (midstance, terminal and pre-swing) (% of gait cycle) | 44.95 (4.3) | A | 44.92 (3.69) | ||
| B | 45.55 (4.1) | ||||
| PL EMG time of peak amplitude (initial contact and loading) (% of gait cycle) | 10.65 (3.4) | A | 10.52 (3.5) | ||
| B | 10.23 (4.6) | ||||
| PL EMG time of peak amplitude (midstance, terminal and pre-swing) (% of gait cycle) | 51.65 (7.0) | A | 50.55 (7.91) | ||
| B | 50.26 (7.61) | ||||
| TA EMG time of peak amplitude (initial contact and loading) (% of gait cycle) | 6.63 (1.4) | A | 6.28 (1.3) | ||
| B | 6.39 (1.4) | ||||
| Zammit and Payne [ | FHSQ reported at baseline and 4 weeks | Increase in FHSQ function subscale (increase in function) | 64.94 (24.0)* | NA | |
| Murley and Bird [ | Over-ground walking (self-selected speed) | PL EMG amplitude (% MVIC) | 88.00 (26.5) | A | 98.00 (32.9) |
| B | 107.00 (35.8) | ||||
| C | 99.00 (32.6) | ||||
| TA EMG amplitude (% MVIC) | 122.00 (38.4) | A | 123.00 (42.2) | ||
| B | 129.00 (43.1) | ||||
| C | 125.00 (30.0) | ||||
| Soleus EMG amplitude (% MVIC) | 256.60 (89.6) | A | 251.93 (95.7) | ||
| B | 255.70 (94.5) | ||||
| C | 260.92 (98.4) | ||||
| Chen et al. [ | Over-ground walking (1.09 ± 0.11 m/s) | Velocity (cm/s) | 108.57 (11.3) | NA | 109.39 (11.1) |
| Cadence (steps/min) | 103.98 (6.8) | NA | 104.73 (5.8) | ||
| Step width(cm) | 15.44 (5.2) | NA | 15.44 (5.0) | ||
| Step length(cm) | 63.09 (4.9) | NA | 61.81 (4.4) | ||
| Stance time (%) | 63.72 (1.7) | NA | 63.93 (1.9) |
FO – foot orthoses, EMG – electromyography, TP – tibialis posterior, PL – peroneus longus, TA – tibialis anterior, RMS – root mean square, MVIC – maximum voluntary isometric contraction, FHSQ – foot health status questionnaire, NA – not applicable, N/A – not available, *No FO condition was prior to orthoses dispense, the FO condition was following four weeks of orthoses use, ^ Median results and significance tabled as per original article– means and standard deviations unavailable.
Figure 2Forest plot of data pooling for the use of FOs for the domain of pain. FHSQ – foot health status questionnaire.
Figure 3Forest plot for data pooling for the domain of rearfoot kinematics. RF – rearfoot, ever – eversion, ft – foot, excur – excursion, vel – velocity, *observed during running.
Figure 4Forest plot of data pooling for the domain of kinetics. Pk – peak, FF – forefoot, lat – lateral, med – medial, vert – vertical, F-t integ – force time integral, RF – rearfoot, mo – moment, inv – inversion, *observed during running.
Figure 5Forest plot of data pooling for the domain of physical function. EMG – electromyography, TP – tibialis posterior, RMS – root mean square, PL – peroneus longus, TA – tibialis anterior, MVIC – maximum voluntary isometric contraction, amp – amplitude, (1) – initial contact and loading, (M) – midstance, terminal and pre-swing.
Outcomes and device review categories of FOs where statistically significant SMDs were observed^ (in descending effect size) (during walking unless otherwise noted)
| Otman et al. [ | III | -4.11 | -5.24 to -2.98 | Physical function | ↓ energy cost at 1.34 m/s, 0 incline (ml.kg.min-1) | NA | 1.14 |
| Redmond et al. [ | IV | 1.13 | 0.49 to 1.77 | Kinetics | ↑ force-time integral (midfoot) (N/s) | A | 284.60 |
| Mündermann et al. [ | IV | -0.94* | -1.58 to -0.30 | Kinetics | ↓ peak loading rate (N/s)* | A | 10.50 |
| Zammit and Payne [ | IV | -0.93 | -1.55 to -0.30 | Pain | ↓ FHSQ pain subscale following 4 weeks of use (%) | NA | 21.00 |
| Mündermann et al. [ | IV | -0.90* | -1.54 to -0.26 | Rearfoot kinematics | ↓ peak foot eversion (°) * | C | 2.30 |
| Hurd et al. [ | IV | -0.78* | -1.52 to -0.03 | Kinetics | ↓ peak RF eversion moments (Nm.kg-1) * | A | 0.52 |
| Mündermann et al. [ | IV | -0.75 | -1.38 to -0.13 | Kinetics | ↓ peak ankle inversion moment (Nm)* | C | 6.00 |
| Murley et al. [ | IV | -0.76 | -1.29 to -0.24 | Physical function | ↓ TP EMG RMS amplitude (initial) (%) | B | 21.93 |
| Zammit and Payne [ | IV | -0.76 | -1.37 to -0.14 | Physical function | ↓ FHSQ function subscale following 4 weeks of use (%) | NA | 20.40 |
| Johanson et al. [ | IV | -0.72 | -1.33 to -0.11 | Rearfoot kinematics | ↓ peak RF eversion (°) | A | 2.15 |
| Mündermann et al. [ | IV | -0.68 | -1.30 to -0.06 | Kinetics | ↓ peak loading rate (N/s)* | B | 7.70 |
| Redmond et al. [ | IV | -0.65 | -1.26 to -0.04 | Kinetics | ↓ force-time integral (lateral FF) (N/s) | A | 337.80 |
| -0.65 | -1.25 to -0.04 | Kinetics | ↓ force-time integral (medial FF) (N/s) | A | 128.20 | ||
| 0.63 | 0.02 to 1.24 | Kinetics | ↑ force at midfoot (N) | A | 38.90 | ||
| Murley et al. [ | IV | -0.58 | -1.10 to -0.07 | Physical function | ↓ TP EMG peak amplitude (initial) (%) | B | 19.43 |
| Murley et al. [ | IV | -0.55 | -1.07 to -0.04 | Physical function | ↑ PL EMG peak amplitude (midstance +) (%) | B | 21.05 |
| Murley et al. [ | IV | -0.54 | -1.06 to -0.03 | Physical function | ↑ PL EMG RMS amplitude (midstance +) (%) | B | 18.66 |
SMD values to the negative favour the FO condition over the no-FO condition.
FO – foot orthoses, RF – rearfoot, EMG – electromyography, TP – tibialis posterior, PL – peroneus longus, RMS – root mean square, FHSQ – foot health status questionnaire, NA – not applicable, *outcomes observed during running. ^Rome and Brown [48] SMDs unavailable.